|
February 10, 2012
|
| 11:58 EDT |  | RHHBY |
|
| 07:10 EDT |  | RHHBY |
|
| 06:18 EDT | | RHHBY |
|
|
February 8, 2012
|
| 05:31 EDT |  | RHHBY |
|
|
February 7, 2012
|
| 16:20 EDT | | RHHBY |
|
| 12:02 EDT | | RHHBY |
|
|
February 3, 2012
|
| 11:26 EDT | | RHHBY |
|
| 11:25 EDT | | RHHBY |
|
|
February 1, 2012
|
| 09:03 EDT | | RHHBY |
|
|
January 31, 2012
|
| 15:58 EDT | | RHHBY |
|
| 12:06 EDT | | RHHBY |
| theflyonthewall.com: | Roche to nominate slate of candidates to Illumina board | | Roche (RHHBY) announced that it has provided notice to Illumina (ILMN) that it will nominate a slate of independent candidates for election to Illumina’s board and propose certain other matters for the consideration of Illumina’s shareholders at Illumina’s 2012 annual meeting, which, if adopted, would result in Roche-nominated directors comprising a majority of the Illumina board. Roche also named five alternate nominees for election to Illumina’s board. Roche will also propose increasing the size of Illumina’s board from nine directors to eleven directors with the resulting vacancies on the board to be filled by candidates nominated by Roche. :theflyonthewall.com |
|
| 07:21 EDT |  | RHHBY |
|
|
January 30, 2012
|
| 11:30 EDT | | RHHBY |
| theflyonthewall.com: | Curis confirms FDA approval for Erivedge | | Curis (CRIS) announced that Erivedge capsule was approved by the FDA for the treatment of adults with a type of skin cancer, called basal cell carcinoma, that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation. Erivedge is the first and only FDA-approved medicine for people with advanced forms of the most common skin cancer. It is being developed and will be commercialized by Roche (RHHBY) and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Curis earned a $10M milestone payment from Genentech as a result of the FDA's approval of Erivedge in this indication and is also entitled to receive royalties on future sales of the product. :theflyonthewall.com |
|
| 11:23 EDT | | RHHBY |
| theflyonthewall.com: | Roche unit confirms FDA approval for Erivedge, jointly developed with Curis | | Genentech, a member of the Roche Group (RHHBY), announced that Erivedge capsule was approved by the U.S. Food and Drug Administration for the treatment of adults with a type of skin cancer, called basal cell carcinoma, that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation. Erivedge is the first FDA-approved medicine for people with advanced forms of the most common skin cancer. Roche and Genentech are also evaluating Erivedge in a Phase II trial in people with operable forms of BCC. Roche is developing Erivedge under a collaboration agreement with Curis, Inc. (CRIS) Curis is eligible to receive cash payments upon the successful achievement of specified clinical development and regulatory approval milestones, as well as royalties upon commercialization of Erivedge. :theflyonthewall.com |
|
| 11:02 EDT | | RHHBY |
| theflyonthewall.com: | FDA approves new treatment for most common type of skin cancer | | Erivedge was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body. rivedge is marketed by South San Francisco based-Genentech, a member of the Roche Group. :theflyonthewall.com |
|
Subscribe for More Information